|本期目录/Table of Contents|

[1]程然,徐小元.卡维地洛治疗肝硬化门静脉高压症新进展[J].传染病信息,2018,02:184-188.
 CHENG Ran,XU Xiao-yuan*.Advances in carvedilol to cirrhotic portal hypertension[J].Infectious Disease Information,2018,02:184-188.
点击复制

卡维地洛治疗肝硬化门静脉高压症新进展(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2018年02期
页码:
184-188
栏目:
综述
出版日期:
2018-03-20

文章信息/Info

Title:
Advances in carvedilol to cirrhotic portal hypertension
作者:
程然徐小元
100034,北京大学第一医院感染疾病科(程然、徐小元)
Author(s):
CHENG Ran XU Xiao-yuan*
Department of Infectious Diseases, Peking University First Hospital, 100034, China
关键词:
门静脉高压非选择性β 受体阻滞剂卡维地洛普萘洛尔
Keywords:
portal hypertension non-selective β-blockers carvedilol propranolo
分类号:
R917.72;R575.21
DOI:
10.3969/j.issn.1007-8134.2018.02.022
文献标识码:
A
摘要:
非选择性β 受体阻滞剂(普萘洛尔、纳多洛尔等)在临床已被用于降低肝硬化门脉高压患者的门静脉压力梯度。 新型非选择性β 受体阻滞剂—— 卡维地洛具有β 和α 受体阻滞剂的双重作用。本文就卡维地洛的药理机制,与普萘洛尔相 比血流动力学应答率,食管胃静脉破裂出血的一级与二级预防,对缓解门静脉高压性胃病的作用,可否用于腹水患者等方面 进行综述,以期更好地指导临床治疗。
Abstract:
Non-selective β-blockers (propranolol, nadolol) have been clinically used in patients with cirrhotic portal hypertension and can reduce portosystemic pressure gradient. Carvedilol, a new non-selective β-blocker, has dual effects of β-and α-blockers. In this paper, the pharmacological mechanism of carvedilol, the hemodynamic response rate between carvedilol and propranolol, primary and secondary prevention of esophagogastric variceal bleeding, remission effect on portal hypertensive gastropathy and suitability in patients with ascites are summarized for providing a better guidance to clinic practice.

参考文献/References

[1] Forouzanfar MH, Alexander L, Anderson HR, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2015, 386(10010):2287-2323.
[2] 中华医学会肝病学分会,中华医学会消化病学分会,中华医 学会内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的 防治指南[J]. 临床肝胆病杂志,2016,32(2):203-219.
[3] 中华医学会外科学分会门静脉高压学组. 肝硬化门静脉高压 症食管、胃底静脉曲张破裂出血的诊治共识(2015 版)[J]. 中华外科杂志,2015,53(12):917-921.
[4] 马骁,刘冰熔. 门静脉高压药物治疗的新进展[J]. 世界华 人消化杂志,2008,16(33):3775-3781.
[5] Lebrec D, Nouel O, Corbic M, et al. Propranolol--a medical treatment for portal hypertension?[J]. Lancet, 1980, 2(8187):180-182.
[6] Frishman WH. Carvedilol[J]. N Engl J Med, 1998, 339(24):1759-1765.
[7] Banares R, Moitinho E, Piqueras B, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis[J]. Hepatology, 1999, 30(1):79-83.
[8] 李学文,华琦. 卡维地洛药理作用机制研究进展[J]. 实用 医学杂志,2005,21(11):1233-1235.
[9] Maharaj S, Seegobin K, Perez-Downes J, et al. Severe carvedilol toxicity without overdose-caution in cirrhosis[J]. Clinical hypertension, 2017, 23:25.
[10] Bhardwaj A, Kedarisetty CK, Vashishtha C, et al. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial[J]. Gut, 2017, 66(10):1838-1843.
[11] Rasool MF, Khalil F, L?er S. Optimizing the clinical use of carvedilol in liver cirrhosis using a physiologically based pharmacokinetic modeling approach[J]. Eur J Drug Metab Pharmacokinet, 2017, 42(3):383-396.
[12] Sinagra E, Perricone G, D'Amico M, et al. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis[J]. Aliment Pharmacol Ther, 2014, 39(6):557-568.
[13] Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J]. Gut, 2013, 62(11):1634-1641.
[14] De BK, Das D, Sen S, et al. Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics[J]. J Gastroenterol Hepatol, 2002, 17(2):183-189.
[15] Banares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis[J]. Hepatology, 2002, 36(6):1367-1373.
[16] Gluud LL, Krag A. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults[J]. Cochrane Database Syst Rev, 2012, 8:CD004544.
[17] Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed[J]. Hepatology, 2009, 50(3):825-833.
[18] Abd ElRahim AY, Fouad R, Khairy M, et al. Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding[J]. Hepatol Int, 2018, 12(1):75- 82.
[19] Shah HA, Azam Z, Rauf J, et al. Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial[J]. J Hepatol, 2014, 4(60):757-764.
[20] Lo GH, Chen WC, Wang HM, et al. Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding[J]. J Gastroenterol Hepatol, 2012, 27(11):1681-1687.
[21] Stanley AJ, Dickson S, Hayes PC, et al. Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding[J]. J Hepatol, 2014, 61(5):1014-1019.
[22] Sarin SK, Sreenivas DV, Lahoti D, et al. Factors influencing development of portal hypertensive gastropathy in patients with portal hypertension[J]. Gastroenterology, 1992, 102(3):994- 999.
[23] Gjeorgjievski M, Cappell MS. Portal hypertensive gastropathy: a systematic review of the pathophysiology, clinical presentation, natural history and therapy[J]. World J Hepatol, 2016, 8(4):231- 262.
[24] 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指 南[J]. 传染病信息,2017,30(5):Ⅰ-ⅩⅦ .
[25] Sersté T, Melot C, Francoz C, et al. Deleterious effects of betablockers on survival in patients with cirrhosis and refractory ascites [J]. Hepatology, 2010, 52(3):1017-1022.
[26] Onali S, Kalafateli M, Majumdar A, et al. Non-selective betablockers are not associated with increased mortality in cirrhotic patients with ascites[J]. Liver Int, 2017, 37(9):1334-1344.
[27] Bossen L, Krag A, Vilstrup H, et al. Nonselective beta-blockers do not affect mortality in cirrhosis patients with ascites: post hoc analysis of three randomized controlled trials with 1198 patient[s J]. Hepatology, 2016, 63(6):1968-1976.
[28] Sinha R, Lockman KA, Mallawaarachchi N, et al. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites[J]. J Hepatol, 2017, 67(1):40-46.

备注/Memo

备注/Memo:
[基金项目] 国家科技重大专项(2018ZX09206005-002,2017ZX10302201);北京市自然科学基金(D161100002716003,D161100002716002, D171100003117005)
[通信作者] 徐小元,E-mail: xiaoyuanxu6@163.com
更新日期/Last Update: 2018-03-20